In this series we’re profiling PATH solutions and technologies that received support from donors like you. Today we’re featuring Sayana® Press. Photo: PATH/Will Boase.
What is Sayana Press?
Injectable contraceptives are in high demand in sub-Saharan Africa and parts of South Asia because they are safe, effective, and each injection provides protection for three months.
Sayana Press is a family planning option that combines a lower dose of the Depo-Provera® contraceptive and a needle in the PATH-developed Uniject™ injection device. This easy-to-use prefilled device is designed to allow lower-level health workers, and even users themselves, to inject the product—increasing access for women who must travel long distances to access family planning options.
What is its impact?
Because of Sayana Press’ unique design, we’re poised to support women to self-inject Sayana Press independently, safely, and effectively outside clinics in the privacy of their own homes. But for this to happen, women must first learn how to correctly administer an injection and accurately calculate their reinjection date.
To increase women’s autonomy, PATH is undertaking new research into the feasibility and impact of self-injection in two countries: Senegal and Uganda.
Sayana Press injections were first made available from health care providers in Senegal and Uganda in 2014. PATH’s self-injection research builds on our coordination of these country-led product introductions, as well as similar initiatives in Burkina Faso and Niger.
What role did private donors play?
Private donors and family foundations served an important role in making Sayana Press available to women in these countries, as well as supported recent Sayana Press home and self-injection research.
How can you support projects like this at PATH?
When you donate to PATH, much needed funds go toward furthering novel and effective solutions like Sayana Press. These innovations improve the health of women, children, and communities around the world where they’re needed most.
Sayana Press and Depo-Provera are registered trademarks of Pfizer Inc. and/or its affiliates. Uniject is a trademark of BD.
- Tracy Romoser is a communications officer and the blog editor at PATH.